Showing 721-730 of 974 results for "".
- Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseaseshttps://modernod.com/news/azura-ophthalmics-to-present-new-data-supporting-the-potential-of-azr-md-001-to-be-the-first-ophthalmic-keratolytic-for-ocular-surface-diseases/2482185/Azura Ophthalmics announced multiple presentations highlighting positive efficacy and safety data from phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in meibomian gland dysfunction (MGD). This includes new, long-term data at ASCRS of the company’s lead drug candidat
- Terry Kim, MD, Joins Alcon as Chief Medical Officer and Head of Global Medical Safetyhttps://modernod.com/news/terry-kim-md-joins-alcon-as-chief-medical-officer-and-head-of-global-medical-safety/2482182/Terry Kim, MD, Professor of Ophthalmology at Duke University Eye Center, will join Alcon in April as Chief Medical Officer (CMO) and Head of Global Medical Safety. Dr. Kim serves as Duke Eye Center’s Chief of the Cornea and External Disease Division, Director of the Refractive Sur
- Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisorhttps://modernod.com/news/opthea-appoints-arshad-m-khanani-md-ma-fasrs-as-chief-medical-advisor/2482120/Opthea announced the appointment of Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor. An internationally recognized retina specialist and clinical scientist, Dr. Khanani is a managing partner, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates, and Clinic
- Ocuphire Pharma Announces Appointment of George Magrath, MD, MS, as Chief Executive Officer and Directorhttps://modernod.com/news/ocuphire-pharma-announces-appointment-of-george-magrath-md-ms-as-chief-executive-officer-and-director/2481927/Ocuphire Pharma announced the appointment of George Magrath, MD, MS, as Chief Executive Officer and member of the Board of Directors, effective today. Dr. Magrath succeeds Rick Rodgers, Interim CEO and President since April 2023. Mr. Rodgers will remain on the company’s Board of Direct
- Alcon Names Daniel M. Miller, MD, PhD, Senior Scientific Advisor to Alcon's R&D team PDFhttps://modernod.com/news/alcon-names-daniel-m-miller-md-phd-senior-scientific-advisor-to-alcons-rd-team-pdf/2481584/Alcon announced that the highly esteemed ophthalmologist, Daniel M. Miller, MD, PhD, will join Alcon as a member of the Research and Development (R&D) team. Dr. Miller is a fellowship-trained medical and surgical retina specialist. He will serve as a Senior Scientific Advisor to Alc
- Azura Ophthalmics to Present New Data on AZR-MD-001 in Meibomian Gland Dysfunction at ASCRS and ARVOhttps://modernod.com/news/azura-ophthalmics-to-present-new-data-on-azr-md-001-in-meibomian-gland-dysfunction-at-ascrs-and-arvo/2481544/Azura Ophthalmics announced multiple presentations featuring positive efficacy and safety data from a phase 2b study of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD). Data will be featured at the upcoming Annual Meetings for the Association for Research
- EyePoint Pharmaceuticals Promotes Jay S. Duker, MD, to President and Chief Operating Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-promotes-jay-s-duker-md-to-president-and-chief-operating-officer/2481320/EyePoint Pharmaceuticals announced that Jay S. Duker, MD, who has served as the company’s Chief Operating Officer (COO) since November 2021, has been promoted to the additional role of President. In addition to continuing to oversee his duties as COO, in his expanded role, Dr. Duker wi
- Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directorshttps://modernod.com/news/iveric-bio-announces-the-addition-of-pravin-u-dugel-md-to-its-board-of-directors/2481317/Iveric bio announced the election of Pravin U. Dugel, MD, President of Iveric Bio, to its Board of Directors, effective as of January 1, 2023. Dr. Dugel has been instrumental in helping to shape the company’s business strategy and in overseeing the development and regulatory submission
- Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunctionhttps://modernod.com/news/azura-ophthalmics-announces-positive-results-from-phase-2b-clinical-trial-of-azr-md-001-in-meibomian-gland-dysfunction/2481247/Azura Ophthalmics announced positive 3-month efficacy and safety results from its phase 2b study of AZR-MD-001 0.5% in Meibomian Gland Dysfunction (MGD). The trial met its co-primary endpoints of improvements in Meibomian Glands Yielding Liquid Secretion (MGYLS; number of open glands) and Oc
- Ophthalmologist Ashley Brissette, MD, Launches New Eye Area Skincare Line Daily Practicehttps://modernod.com/news/ophthalmologist-ashley-brissette-md-launches-new-eye-area-skincare-line-daily-practice/2480861/Daily Practice, a new eye care line by Ashley Brissette (Dr. B), MD, launched with a product called ‘Eye Revive.’ Having worked as an ophthalmologist for 6 years, New York City-based Dr. B said she recognized a growing trend of eye irritation, sensitivity and